New Evidence Available

Updated Recommendation

A new evidence synthesis was published:2025, WHO consolidated guidelines on tuberculosis: module 3: diagnosis

View latest version (2025)

Bibliographic information

GuidelineWHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection, 3rd ed.
Year of Publication2024
Issuing InstitutionWorld Health Organization

Recommendation

Retired

In children with signs and symptoms of pulmonary TB, Xpert MTB/RIF should be used as an initial diagnostic test for TB and rifampicin-resistance detection in sputum, gastric aspirate, nasopharyngeal aspirate and stool rather than smear microscopy/culture and phenotypic DST.

Recommended in favor

Strong

Notes and Remarks

Remarks Sputum includes expectorated and induced sputum. Studies assessing the impact of Xpert MTB/RIF on outcomes in children are lacking. The choice of the specimen will depend on the acceptability (for children, parents, health care workers and other stakeholders) and the feasibility of collecting and preparing specimens in the local context. Regarding Xpert MTB/RIF, the certainty of evidence is higher for sputum and nasopharyngeal aspirates than for other specimen types. The recommendation can be extrapolated for children living with HIV. The direct benefit from testing for rifampicin resistance in sputum (very low certainty of evidence for test accuracy) can be extrapolated to other specimens.

Also Featured In

This recommendation also appears in the following guidelines:

Originally Developed
Guideline

WHO consolidated guidelines on tuberculosis: module 3: diagnosis – rapid diagnostics for tuberculosis detection: web annex 2. GRADE profiles

Year2020
InstitutionWHO
Guideline

WHO consolidated guidelines on tuberculosis: module 3: diagnosis – rapid diagnostics for tuberculosis detection: web annex 2. GRADE profiles

Year2020
InstitutionWHO